Diverse effects of statins on endothelial cells?

References
1 Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study. Lancet 1994; 344: 1383-9.
2 The long-term intervention with prevastatin in ischaemic disease (LIPID) study group.. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
3 Sacks FM, Pfeffer MA, Moye LA. et al The effect pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators.. N Engl J Med 1996; 335: 1001-9.
4 Sheperd J, Cobbe SM, Ford I. et al et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.. N Engl J Med 1995; 333: 1301-7.
5 Downs JR, Clearfield M, Weis S. et al Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAexCAPS. Air Force Texas. Coronary Atherosclerosis Prevention Study.. JAMA 1998; 279: 1615-22.
6 Crouse JR. et al HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trial data.. Atherosclerosis 1998; 138: 11-24.
7 Corsini A. et al New insights into the pharmacodynamic and pharmacokinetics properties of statins.. Pharmacol Ther 1999; 84: 413-28.
8 Callahan AS. Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms.. Curr Atheroscl Rep 2003; 5: 33-7.
9 Bellosta S, Ferri N, Bernini F. et al Non-lipid related effects of statins.. Ann Med 2000; 32: 164-76.
10 Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors.. Arterioscler Thromb Vasc Biol 2001; 21: 1712-9.
11 Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor on the expression of adhesion molecules on human monocyte cell line.. Int J Immunopharmacol 1996; 18: 669-75.
12 Weitz-Schmidt G, Welzenbach K, Brinkmann V et al. Statins selectively inhibit leukocyte function antigen –1 by binding to a novel regulatory integrin site.. Nat Med 2001; 7: 687-92.
13 Lefer AM, Campbell B, Shin Y. et al Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts.. Circulation 1999; 100: 178-84.
14 Scalia R, Gooszen ME, Jones SP. et al Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice.. Circulation 2001; 103: 2598-603.
15 Huhle G, Abletshauser C, Mayer N. et al Reduction of platelet activity markers in type II hypercholesterolemic patients with HMG-CoA reductase inhibitor.. Thromb Res 1999; 95: 229-34.
16 Aikawa M, Rabkin E, Sugiyama S. et al An HMG-CoA reductase inhibitor, cerivastatin suppresses growth of macrophages expressing matrix metallo-proteinases, and tissue factor in vivo, and in vitro.. Circulation 2001; 103: 276-83.
17 Colli S, Eligini S, Lalli M. et al Vastatin inhibits tissue factor in cultured human macrophages.. Arterioscler Thomb Vasc Biol 1997; 17: 265-72.
18 Inoue I, Goto S, Mizotani K. et al Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1b, interleukin-6, cyclooxigenase-2 and p22 phox by regulation of peroxisome proliferators-activated receptor g (PPAR-g) in primary endothelial cells.. Life Sci 2000; 67: 863-76.
19 Essig M, Nguyen G, Prie D. et al 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins.. Circ Res 1998; 83: 683-90.
20 Bourcier T, Libby P. HMG-CoA reductase inhibitor reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells.. Arterioscler Thromb Vasc Biol 2000; 20: 556-62.
21 Kwak B, Mulhaupt F, Myit S. et al Statins as a newly recognized type of immunomodulator.. Nat Med 2000; 6: 1399-402.
22 Colli S, Eligini S, Lalli M. et al Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis.. Arterioscler Thromb Vasc Biol 1997; 17: 265-72.
23 Camera M, Toschi V, Comparato C. et al Cholesterol-induced thrombogenicity of the vessel wall: inhibitory effect of fluvastatin.. Thromb Haemost 2002; 87: 748-55.
24 Eto M, Luscher TF. Modulation of coagulation and fibrinolytic pathways by statins.. Endothelium 2003; 10: 35-41.
25 Romano M, Diomede L, Sironi M. et al Inhibition of monocyte-chemotactic protein-1 synthesis by statins.. Lab Invest 2000; 80: 1095-100.
26 Stalker T, Lefer AM, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid.. Br J Pharmacol 2001; 133: 406-12.
27 Sparrow CP, Burton CA, Hernandez M. et al Simvastatin has anti-inflammatory and anti-atherosclerotic activities independent of plasma cholesterol lowering.. Arterioscler Thromb Vasc Biol 2001; 21: 115-21.
28 Rosenson R, Tangnery C. Anti-atherothrombotic properties of statins.. JAMA 1998; 279: 1643-50.
29 Fenton JWH. et al Statins induce hypothrombotic states?. Clin Appl Thromb Hemost 2000; 6: 18-21.
30 Eto M, Kozai T, Cosentino F. et al Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways.. Circulation 2002; 105: 1756-9.
31 Bea F, Blessing E, Shelley MI. et al Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation.. Atherosclerosis 2003; 167: 187-94.
32 Meroni PL, Raschi E, Testoni C. et al Statins prevent endothelial cell activation induced by antiphospholipid (anti- β 2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype.. Arthritis Rheum 2001; 44: 2870-8.
33 Ferrara DE, Liu X, Espinola RG. et al Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model.. Arthritis Rheum 2003; 48: 3272-9.
34 Ferrara DE, Swerlick R, Casper K. et al Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells.. J Thromb Haemost 2004; 2: 1558-63.
35 Dimitrova Y, Dunoyer-Geindre S, Reber G. et al Effects of statins on adhesion molecule expression in endothelial cells.. J Thromb Haemost 2003; 1: 2290-9.
36 Schmidt A, Goepfert C, Feitsma K. et al Lovastatin-stimulated superinduction of E-selectin, ICAM-1 and VCAM-1 in TNF- α activated human vascular endothelial cells.. Atherosclerosis 2002; 164: 57-64.
37 Rasmussen LM. et al Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells.. Biochem J 2001; 360: 363-70.
38 Bernot D, Benodiel AM, Peiretti F. et al Effect of atorvastatin on adhesive phenotype of human endothelial cells activated by tumor necrosis factor- α.. J Cardiovasc Pharmacol 2003; 41: 316-24.
39 Dunoyer-Geindre S, Dimitrova J, Fish RJ. et al Fluvastatin increases the expression of adhesion molecules, MCP-1 and tissue factor in HUVEC stimulated by patient IgG fractions containing antiphospholipid antibodies.. Thromb Haemost 2005; 93: 339-45.
40 Li X, Liu L, Tupper JC. et al Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells.. J Biol Chem 2002; 277: 15309-16.
41 Eunson T, Kay MA, Wilson CB. et al NF- κ B activation is required for human endothelial survival during exposure to tumor necrosis factor- α but not to Interleukin-1ß or lipopolysaccharide.. J Biol Chem 1999; 274: 28808-15.
42 De Staercke C. et al Differential responses of human umbilical and coronary artery endothelial cells to apoptosis.. Endothelium 2003; 10: 71-8.
43 Bombeli T. et al Apoptotic vascular endothelial cells become procoagulant. Blood 1997; 89: 2429-42.
44 Hebert MJ. et al Apoptosis of endothelial cells is associated with paracrine induction of adhesion molecules: evidence for an interleukin-1beta-dependent paracrine loop.. Am J Pathol. 1998; 152: 523-32.
45 Gorgoulis VG. et al p53 activates ICAM-1 (CD54) expression in an NF-κ B-independent manner.. EMBO J 2003; 22: 1567-78.
46 Guijarro C. et al 3-hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture.. Circ Res 1998; 83: 490-500.
47 Blanco-Colio LM, Villa A, Ortego M et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation.. Atherosclerosis 2002; 161: 17-26.
48 Urbich C, Dernbach E, Zeiher AM. et al Doubleedged role of statins in angiogenesis signaling.. Circ Res 2002; 90: 737-44.
49 Takahashi M, Ogata Y, Okazaki H. et al Fluvastatin enhances apoptosis in cytokine-stimulated vascular smooth muscle cells.. J Card Pharm 2002; 39: 310-1.